Treatment for Shingles on Head
For herpes zoster affecting the scalp and forehead (herpes zoster ophthalmicus), start oral antiviral therapy immediately—preferably valacyclovir 1000 mg three times daily or famciclovir 500 mg three times daily for 7 days—within 72 hours of rash onset to prevent vision-threatening complications and reduce pain. 1, 2
Antiviral Therapy: First-Line Treatment
The cornerstone of treatment is systemic antiviral medication, which must be initiated as early as possible:
Preferred Regimens (in order of preference):
- Valacyclovir 1000 mg orally three times daily for 7 days 3, 2
- Famciclovir 500 mg orally three times daily for 7 days 3, 2
- Acyclovir 800 mg orally five times daily for 7 days 1, 4
Why valacyclovir or famciclovir over acyclovir? High-quality systematic review evidence demonstrates that valacyclovir and famciclovir provide superior pain reduction compared to acyclovir, with 36-46% risk reduction in herpes zoster-associated pain at 21-30 days (NNT=3). 2 Additionally, their superior pharmacokinetics and more convenient dosing (3 times daily vs. 5 times daily) make them the preferred options. 2, 5
Critical Timing
Antiviral therapy is most effective when started within 72 hours of rash onset, though treatment should still be initiated even if this window has passed, particularly for head and neck involvement. 1, 5 The evidence shows that early treatment shortens healing time, reduces acute pain severity, and may decrease the risk of postherpetic neuralgia. 5, 6
Why Head/Forehead Involvement Demands Urgent Treatment
Herpes zoster ophthalmicus (affecting the ophthalmic division of the trigeminal nerve) is potentially sight-threatening and affects 4-20% of all zoster cases. 7 This location carries high risk for:
- Vision loss from corneal involvement
- Acute conjunctivitis
- Keratitis
- Uveitis
- Episcleritis
- Secondary glaucoma 3, 8
This is an urgent indication for systemic antiviral therapy regardless of patient age. 5 While treatment is especially indicated in patients over 50 years, head and neck involvement warrants treatment at any age. 9, 5
Pain Management: Essential Adjunctive Therapy
Antivirals alone are insufficient—concurrent pain management is critical:
Acute Pain (during active infection):
- Analgesics (dose appropriately for pain severity)
- Neuroactive agents: Amitriptyline or gabapentin started early 9, 5
If Postherpetic Neuralgia Develops (pain >90 days):
First-line options include:
- Gabapentinoids (gabapentin or pregabalin)
- Tricyclic antidepressants (amitriptyline)
- SNRIs (duloxetine, venlafaxine)
- Topical treatments: Lidocaine patches or capsaicin as adjuncts 6, 10
Note on corticosteroids: While some older evidence suggested corticosteroids might reduce acute pain duration, they have no proven effect on preventing postherpetic neuralgia and are not routinely recommended. 9, 5
Special Considerations for Ocular Involvement
If there is any eye involvement or the rash extends to the tip of the nose (Hutchinson's sign):
- Urgent ophthalmology referral is mandatory 3
- Continue systemic antivirals as above
- Ophthalmologist may add topical antivirals (ganciclovir 0.15% gel) for conjunctival involvement 3
- Avoid topical corticosteroids in the acute phase unless under ophthalmology supervision, as they can potentiate viral replication 3
Common Pitfalls to Avoid
Delaying treatment while awaiting laboratory confirmation: Diagnosis is clinical—start antivirals immediately based on characteristic dermatomal rash 5
Using acyclovir when valacyclovir/famciclovir are available: The evidence clearly favors newer agents for better outcomes and compliance 2
Inadequate pain management: Pain control should be aggressive from the start, not reserved for postherpetic neuralgia 5, 6
Missing ophthalmology referral: Any forehead/scalp involvement warrants ophthalmology evaluation due to proximity to the ophthalmic nerve 3, 7
Topical acyclovir: This is substantially less effective than oral therapy and should not be used 1, 11
Prevention for Future Episodes
After recovery, strongly recommend recombinant zoster vaccine (Shingrix) for patients ≥50 years old, which demonstrates 67-93% effectiveness in preventing herpes zoster ophthalmicus and 76% effectiveness against postherpetic neuralgia. 12, 7 This vaccine is preferred over the older live attenuated vaccine (Zostavax) due to superior efficacy. 12, 13